These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 31298754)

  • 1. Erratum: Jeter JM, Bowles TL, Curiel-Lewandrowski C, et al. Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer. 2019:125:18-44.
    Cancer; 2019 Aug; 125(15):2706. PubMed ID: 31298754
    [No Abstract]   [Full Text] [Related]  

  • 2. The search for a chemoprevention agent effective against melanoma: considerations and challenges.
    Ming ME
    J Invest Dermatol; 2011 Jul; 131(7):1401-3. PubMed ID: 21673707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bayesian monitoring of phase II trials in cancer chemoprevention.
    Cronin KA; Freedman LS; Lieberman R; Weiss HL; Beenken SW; Kelloff GJ
    J Clin Epidemiol; 1999 Aug; 52(8):705-11. PubMed ID: 10465313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What about chemoprevention for melanoma?
    Demierre MF
    Curr Opin Oncol; 2006 Mar; 18(2):180-4. PubMed ID: 16462188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoprevention of melanoma: an unexplored strategy.
    Demierre MF; Nathanson L
    J Clin Oncol; 2003 Jan; 21(1):158-65. PubMed ID: 12506185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous melanoma: pathogenesis and rationale for chemoprevention.
    Demierre MF; Sondak VK
    Crit Rev Oncol Hematol; 2005 Mar; 53(3):225-39. PubMed ID: 15718148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modeling the solid-liquid phase transition in saturated triglycerides.
    Pink DA; Hanna CB; Sandt C; MacDonald AJ; MacEachern R; Corkery R; Rousseau D
    J Chem Phys; 2010 Feb; 132(5):054502. PubMed ID: 20136317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoprevention of melanoma: theoretical and practical considerations.
    Demierre MF; Sondak VK
    Cancer Control; 2005 Oct; 12(4):219-22. PubMed ID: 16258492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin cancer chemoprevention: strategies to save our skin.
    Einspahr JG; Bowden GT; Alberts DS
    Recent Results Cancer Res; 2003; 163():151-64; discussion 264-6. PubMed ID: 12903851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The state-of-the-art in chemoprevention of skin cancer.
    Stratton SP; Dorr RT; Alberts DS
    Eur J Cancer; 2000 Jun; 36(10):1292-7. PubMed ID: 10882869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Models for early chemoprevention trials in breast cancer.
    Fabian CJ; Kimler BF; Elledge RM; Grizzle WE; Beenken SW; Ward JH
    Hematol Oncol Clin North Am; 1998 Oct; 12(5):993-1017. PubMed ID: 9888018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of phase III clinical trials of prostate cancer chemoprevention.
    Thorpe JF; Jain S; Marczylo TH; Gescher AJ; Steward WP; Mellon JK
    Ann R Coll Surg Engl; 2007 Apr; 89(3):207-11. PubMed ID: 17394699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical evaluation of cancer chemoprevention agents: defining and contrasting phase I, II, and III objectives.
    Goodman GE
    Cancer Res; 1992 May; 52(9 Suppl):2752s-2757s. PubMed ID: 1563007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker end-points in cancer chemoprevention trials.
    Boone CW; Kelloff GJ
    IARC Sci Publ; 1997; (142):273-80. PubMed ID: 9354926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The scientific impact and value of large, NCI-sponsored randomized phase III cancer chemoprevention trials.
    Unger JM; Barlow WE; Tangen CM; Ramsey SD; Thompson IM; Klein EA; LeBlanc M; Blanke CD; Goodman PJ; Minasian LM; Nghiem VT; Hershman DL
    Cancer Epidemiol; 2018 Aug; 55():117-122. PubMed ID: 29936140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melanoma chemoprevention.
    Francis SO; Mahlberg MJ; Johnson KR; Ming ME; Dellavalle RP
    J Am Acad Dermatol; 2006 Nov; 55(5):849-61. PubMed ID: 17052492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melanoma chemoprevention: a role for statins or fibrates?
    Dellavalle RP; Nicholas MK; Schilling LM
    Am J Ther; 2003; 10(3):203-10. PubMed ID: 12756427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice.
    Pommergaard HC; Burcharth J; Rosenberg J; Raskov H
    Anticancer Res; 2013 Aug; 33(8):3033-9. PubMed ID: 23898057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemoprevention of skin melanoma: facts and myths.
    Uzarska M; Czajkowski R; Schwartz RA; Bajek A; Zegarska B; Drewa T
    Melanoma Res; 2013 Dec; 23(6):426-33. PubMed ID: 24077511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
    Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.